Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief, Winship Cancer Institute,Emory University,
Atlanta, GA
Ms Gleason is Advanced Practice Provider Chief, Winship Cancer Institute, Emory University, Atlanta, GA, where she oversees the clinical practice, quality, safety, education, and the Advanced Practice Provider Fellowship Program. Ms Gleason obtained her bachelor’s degree in nursing and master’s degree in nursing with a subspecialty in oncology from Emory University. Her clinical practice focuses around multiple myeloma, including retreatment settings, multidisciplinary care, novel therapies, and patient support. In addition, Ms Gleason is responsible for development and oversight of oncology advanced practice guidelines.
Authored Items
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
September 10, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their personal experiences with patient support groups for multiple myeloma patients that deal with pharmacy issues, financial problems, management of pain and neuropathy, psychological and nutritional support.
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
August 20, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, share their experiences with complex treatment regimens that include oral therapy, especially as it relates to patients’ appropriate adherence to therapy.
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
August 6, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their perspectives on using SQ treatments for MM, including the benefits for the patients, along with a requirement for education and training for nurses with respect to delivering a high volume injection into the SQ space.
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
July 15, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, describe their approach to advising patients on combination therapy, especially with multidrug regimens, and counseling them on treatments that may be needed to prevent or treat therapy-related adverse events.
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
July 13, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, provide their perspectives on how to counsel patients on the best frontline treatment options for newly-diagnosed MM, and how this differs from relapsed/refractory MM, where individualizing treatment plans based on the patient needs and tolerability of treatment is key.
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
June 22, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
June 15, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss the convenience of oral therapy along with challenges in adherence to oral therapy. Additionally, they’ll discuss the tolerability of emerging drugs, the emergence of novel adverse events with new agents, and best practices in providing supportive care for patients on these novel agents.
June 2, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, talk about the emerging treatments for MM, including monoclonal antibodies, 2nd-generation protease inhibitors, and targeted therapies. These changes pose challenges to healthcare providers struggling to keep up with these changes, but this is good news for patients with expanding treatment options.
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
April 23, 2020 | Video Library
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
April 22, 2020 | Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C discuss their approach to the care of transplant-eligible patients with multiple myeloma, particularly based on the patients' risk stratification, as well as poor-prognosis cytogenetics including those with (4,14) translocation.
Last modified: April 7, 2022
